Discovery of a functionally selective serotonin receptor (5-HT1AR) agonist for the treatment of pain
- Sci Adv. 2025 Jun 20;11(25):eadv9267. doi: 10.1126/sciadv.adv9267.
- 1. Department of Chemistry and Pharmacy, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
- 2. Department of Anatomy, University of California, San Francisco, CA, USA.
- 3. Rudolf-Virchow-Center, Julius-Maximilians-Universität, Würzburg, Germany.
- 4. Department of Pharmaceutical Chemistry, University of California, San Francisco, CA, USA.
- 5. Graduate Program in Biophysics, University of California, San Francisco, CA, USA.
- 6. Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan.
- 7. Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto, Japan.
- 8. FAU NeW, Erlangen, Germany.
The heterotrimeric G protein-coupled serotonin receptor 5-HT1A receptor (5-HT1AR) mediates antinociception and may serve as a valuable target for the treatment of pain. Starting from a chemical library, we evolved ST171, a bitopic 5-HT1AR agonist that revealed highly potent and functionally selective Gi/o signaling without Gs activation and marginal β-arrestin recruitment. ST171 is effective in acute and chronic pain models. Cryo-electron microscopy structures of ST171 bound to 5-HT1AR in complex with the Gi protein compared to the canonical agonist befiradol bound to complexes of 5-HT1AR with Gi or Gs revealed that the ligands occupy different exo-sites. The individual binding poses are associated with ligand-specific receptor conformations that were further studied by molecular dynamics simulations, allowing us to better understand ligand bias, a phenomenon that may be crucial to the discovery of more effective and safe G protein-coupled receptor drugs.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: 5-HT ReceptorResearch Areas: Neurological Disease